Direkt zum Inhalt
Merck

Emerging therapies in rosacea.

Journal of the American Academy of Dermatology (2013-11-28)
Alison Layton, Diane Thiboutot
ZUSAMMENFASSUNG

Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Doxycyclin -hyclat
Sigma-Aldrich
Ivermectin
Supelco
Permethrin, PESTANAL®, analytical standard
Supelco
Doxycyclin -hyclat, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Doxycycline monohydrate
Ivermectin, European Pharmacopoeia (EP) Reference Standard
Supelco
Doxycyclin -hyclat, VETRANAL®, analytical standard